Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. Lecanemab is suspected of causing at least three deaths.

Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease

Albemarle

Dollar General

DexCom

Enphase Energy

Etsy

First Solar

Halliburton

Organon & Co

SolarEdge Technologies

Most S&P 500 investors lost nearly 20% this year. But plenty of moneymaking stocks jumped higher.

12 Stocks Turned $10,000 To $277,126 In 12 Months

The FDA's approval process of Biogen's Alzheimer's drug was questioned in a Congressional report released Thursday.

House committee questions Biogen drug approval process

CRISPR Therapeutics

Vertex Pharmaceuticals

Pharma and biotech stocks are enjoying tailwinds as part of the broad market rally today.

3 Biotech Stocks to Watch Heading Into 2023

A new as-yet-unreported death among those taking Biogen's Lecanemab in an extended post-Phase 3 study has emerged. Biogen's Lecanemab has a PDUFA date of January 6, 2023; the FDA will announce its preliminary (or final) approval or rejection.

Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels

The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was "rife with irregularities," a congressional report showed on Thursday.

Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drug

Netflix

NIKE

The analysts are rewarding companies that prove they can succeed in the face of headwinds and the most upgraded in Q4 2022 are Netflix, Biogen and Nike.

The Top Three Stocks Analysts Say To Buy

Even at a discount, investors may be taking on a big risk with Biogen.

Is Biogen's Stock Too Risky to Invest in?

Gilead Sciences

NVIDIA

Should you jump on the bandwagon and buy these surging stocks?

3 Nasdaq Stocks That Are Up 25% in 3 Months

1 Green Flag and 1 Red Flag for Biogen

Best Buy

Capital One

eBay

Intel

Liberty Global Ltd

Lowe's

Lumen Technologies

LyondellBasell Industries

Altria

Oracle

Regeneron Pharmaceuticals

Sirius XM Holdings Inc

Seagate Technology Holdings PLC

Synchrony Financial

Vodafone Group

The top net payout yield stock failed to match the total return of the S&P 500 during 2H '22 as tech stocks soared. The top net payout yield stocks averaged massive 19.6% yields to start December, as normal capital return plans returned during 2022.

Top Net Payout Yields - December 2022

CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab. Under the terms of the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the companies long-standing collaboration on antibodies targeting CD20.

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

BioNTech SE

Incyte

Inspire Medical Systems Inc

Eli Lilly

Veeva Systems

Viatris

Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks.

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

These stocks have climbed by double digits this year.

Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move

Both stocks are heading for double-digit gains this year.

Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock

EXTON, Pa. , Dec. 12, 2022 /PRNewswire/ -- Frontage's Bioanalytical team partnered with Eisai/Biogen to support the PK and PD biomarker bioanalysis of lecanemab (BAN2401) in their investigational global phase 3 study in US and China. Recently Eisai/Biogen publicly shared the favorable results of the lecanemab (BAN2401) Clarity AD study which Eisai presented on November 29, 2022, at the Clinical Trials on Alzheimer's Disease Congress (CTAD), and published the findings in NEJM.

Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, Lecanemab

Bio-Techne

BIIB vs. TECH: Which Stock Is the Better Value Option?

CAMBRIDGE, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody.

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Biogen (BIIB) Stock Undervalued Right Now?

Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression

Investors will soon learn if the company's Alzheimer's treatment gets the green light.

Why 2023 Could Be a Big Year for Biogen

Atai Life Sciences BV

SAGE Therapeutics

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

Biogen Inc. (NASDAQ:BIIB ) Biogen and Sage Zuranolone Webcast December 6, 2022 8:00 AM ET Company Participants Helen Rubinstein – Director-Investor Relations-Sage Therapeutics Chris Benecchi – Chief Business Officer-Sage Therapeutics Maha Radhakrishnan – Group Senior Vice President and Chief Medical Officer-Biogen Greg Mattingly – Associate Clinical Professor-Washington University Alisha Alaimo – President-Biogen-U.S. Organization Mike Hencke – Head-Investor Relations-Biogen Jim Doherty – Chief Development Officer-Sage Therapeutics Conference Call Participants Operator Good morning. Welcome to Sage Therapeutics and Biogen's Joint Investor Webcast.

Biogen Inc. (BIIB) Biogen and Sage Zuranolone Webcast Transcript

Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.

Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD. The submission completes the NDA filing that was initiated earlier this year.

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

News for Biogen Stock (BIIB)